Stockscreener 앱 받기
2.03
6.28%
0.12
시간 외 거래:
2.03
전일 마감가:
$1.91
열려 있는:
$1.9
하루 거래량:
3.28M
Relative Volume:
2.83
시가총액:
$147.14M
수익:
-
순이익/손실:
$-44.95M
주가수익비율:
-2.2745
EPS:
-0.8925
순현금흐름:
$-56.37M
1주 성능:
+17.34%
1개월 성능:
+65.04%
6개월 성능:
+46.04%
1년 성능:
+10.93%
1일 변동 폭
$1.885
$2.05
1주일 범위
$1.6709
$2.05
52주 변동 폭
$0.8719
$2.99
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
2.03 | 98.58M | 0 | -44.95M | -56.37M | -0.8925 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-08-28 | 개시 | Jefferies | Buy |
| 2025-06-03 | 재개 | Piper Sandler | Overweight |
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright - Yahoo Finance
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next - TipRanks
Biomea Fusion to Participate in Upcoming Investor Conferences - investingnews.com
BMEA Surges 6.85%: Biomea Fusion Approaches Key $1.88 ResistanceQuote Data - vinanet.vn
BMEA Should I Buy - Intellectia AI
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Biomea Shares Rise After Completing Enrollment in Diabetes Trial - marketscreener.com
Biomea Fusion stock surges on diabetes trial enrollment completion By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Biomea Fusion stock rating on trial enrollment By Investing.com - Investing.com UK
Why is Biomea Fusion stock climbing today? By Investing.com - Investing.com India
Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes - TradingView
Biomea Fusion completes enrollment in diabetes trial By Investing.com - Investing.com UK
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it? - TradingView
Biomea Fusion completes enrollment in diabetes trial - Investing.com
Biomea (BMEA) Quarterly Results: Profit Per Share Clears Its Benchmark at the Close; Investor Response - vinanet.vn
Biomea Fusion begins dosing first participant in OPAL study arm for new combination therapy - Traders Union
Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure - Kalkine Media
Biomea Fusion shares new insights on three stages of type 1 diabetes in expert webinar - Traders Union
Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com - Investing.com Canada
Biomea Fusion doses first patient in icovamenib-semaglutide study - Investing.com
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity - The Manila Times
Biomea Fusion Initiates OPAL Study Arm of Icovamenib Plus Low-Dose Semaglutide in Obesity Research - Quiver Quantitative
Biomea Fusion Trial Tests Obesity Drug Combo Beyond Weight Loss - Stock Titan
Renaissance Technologies LLC Grows Position in Biomea Fusion, Inc. $BMEA - MarketBeat
Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BMEA Q2 2026 Earnings: Narrower Loss Delivers 47% EPS Surprise as Pipeline Progress ContinuesEarnings Outlook Update - vinanet.vn
HC Wainwright Expects Stronger Earnings for Biomea Fusion - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion Stock (BMEA) Opinions on Clinical Milestones and Liquidity Concerns - Quiver Quantitative
Icovamenib clinical enrollment opens for type 2 diabetes study, Biomea Fusion initiates - Traders Union
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Citizens JMP Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Biomea Fusion Inc (BMEA) Stock News Today - TradingKey
Biomea Fusion explores new scientific approaches to diabetes treatment - Traders Union
Oppenheimer Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Biomea Fusion (BMEA) Edges Higher: Bounces Off Support as Oversold Conditions EaseIndex Put Call - dars.gov.et
Biomea Fusion, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Biomea Fusion (NASDAQ:BMEA) Issues Earnings Results - MarketBeat
Biomea Fusion Q2 loss narrows, cash runway into Q2 2027 - TradingView
Biomea Fusion (NASDAQ: BMEA) trims R&D, discloses going concern risk - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights - Yahoo Finance
Biomea Fusion (BMEA) Gains 2.56% to $1.2 as Key Levels Come into FocusStock Surge Alerts - dars.gov.et
Participants sought for type 2 diabetes trial evaluating icovamenib, Biomea Fusion announces - Traders Union
Biomea Fusion Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
BMEA Q2'26 Earnings: EPS estimate is (0.22) USD - tradingview.com
Biomea Fusion (BMEA) Nears Key Support as Selling Pressure ContinuesMA Crossover - vinanet.vn
Biomea Fusion (BMEA) to Post Earnings on Tuesday - MarketBeat
Biomea Fusion Inc (BMEA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomea Fusion Inc (BMEA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BMEA|Biomea Fusion Inc|Price:1.250|Chg%:-0.010 - TradingKey
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오미아 퓨전 주식 (BMEA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hitchcock Michael J.M. | Interim CEO |
Dec 02 '25 |
Buy |
0.99 |
100,000 |
99,180 |
115,000 |
| Erdtmann Rainer M | See Remarks |
Nov 28 '25 |
Buy |
1.10 |
40,000 |
44,052 |
683,027 |
| Erdtmann Rainer M | See Remarks |
Dec 01 '25 |
Buy |
1.05 |
10,000 |
10,500 |
693,027 |
0.86%
0.31%
자본화:
|
볼륨(24시간):